Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading 1.3% Higher

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) were up 1.3% during trading on Wednesday . The stock traded as high as $88.12 and last traded at $87.23. Approximately 327 shares traded hands during trading, a decline of 88% from the average daily volume of 2,689 shares. The stock had previously closed at $86.08.

Analyst Upgrades and Downgrades

Separately, BTIG Research initiated coverage on shares of Zealand Pharma A/S in a research note on Thursday, March 7th. They issued a “buy” rating for the company.

Zealand Pharma A/S Stock Performance

The stock has a market cap of $4.49 billion, a price-to-earnings ratio of -47.93 and a beta of 0.63. The stock’s 50-day simple moving average is $91.99 and its two-hundred day simple moving average is $66.60.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its earnings results on Tuesday, February 27th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.08). The business had revenue of $3.35 million for the quarter, compared to the consensus estimate of $1.97 million. Zealand Pharma A/S had a negative net margin of 203.99% and a negative return on equity of 49.78%. As a group, research analysts predict that Zealand Pharma A/S will post -2.56 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.